Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

Core Viewpoint - Mural Oncology plc has announced the effective completion of a scheme of arrangement under which XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, will acquire the entire issued share capital of Mural as of December 5, 2025 [1]. Group 1: Acquisition Details - The acquisition scheme became effective on December 5, 2025, allowing XRA 5 Corp. to acquire all shares of Mural [1]. - Distribution of cash consideration to Mural's shareholders is expected to begin shortly after the effective date, with completion anticipated by December 19, 2025 [2]. - Mural's shares were officially canceled from trading on the Nasdaq Global Market as of 8:00 PM (U.S. Eastern Time) on December 4, 2025 [3]. Group 2: Regulatory Compliance - The announcement complies with the Irish Takeover Rules, and the directors of Mural have confirmed the accuracy of the information provided [7]. - The announcement will be made available on Mural's website in accordance with Rule 26.1 of the Irish Takeover Rules [12].